Contact Congress about H.R. 1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Generic drug companies could ask the FDA whether their drug matches the brand-name drug’s inactive ingredients. The FDA would have to name the differences and usually stick with its answer after the application is filed.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. is a House bill in committee. The latest recorded action: Referred to the House Committee on Energy and Commerce.

Latest action on H.R. 1843: Referred to the House Committee on Energy and Commerce.

Who this affects: This bill mainly affects generic drug companies and FDA staff who review generic drug applications. It could also matter to brand-name drug companies because the FDA would share more detail about inactive ingredient differences. Patients would not see a direct change in insurance coverage or drug prices from the bill itself.

Why this matters: Generic drug makers can lose time and money if they do not know why the FDA thinks their product does not match a brand-name drug. This bill would make the FDA give more exact answers about inactive ingredients and amounts. That could make applications easier to prepare and reviews more predictable. Still, the bill does not guarantee cheaper drugs or faster approvals.

Key provisions in H.R. 1843

• The FDA would have to answer when a company asks whether a proposed generic drug matches the brand-name drug’s inactive ingredients. The answer must cover both the ingredients and their amounts.
• If the FDA says the drugs do not match, it must name the inactive ingredients that are different. If the amount is different, the FDA must say how large the difference is.
• The FDA could share this ingredient information when a company asks. It could also share it on its own while reviewing the generic drug application.
• After a generic application is filed, the FDA usually could not change an earlier finding that the inactive ingredients match. It could change that finding only if the brand formula is removed for safety or effectiveness reasons, or if the FDA explains an error in writing.
• The bill says these FDA disclosures are legally allowed. That includes the federal law that protects trade secrets and confidential business information, known as 18 U.S.C. section 1905.

How Modern Action helps you take action on H.R. 1843

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 1843

What is H.R. 1843?

Generic drug companies could ask the FDA whether their drug matches the brand-name drug’s inactive ingredients. The FDA would have to name the differences and usually stick with its answer after the application is filed.

How do I support or oppose H.R. 1843?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about H.R. 1843?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain H.R. 1843 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.